Association between SLC17A7 gene polymorphisms and venlafaxine for major depressive disorder in a Chinese Han population: a prospective pharmacogenetic case-control study

Liangjie Liu, Decheng Ren, Fan Yuan, Yan Bi, Zhenming Guo, Gaini Ma, Fei Xu, Binyin Hou, Lei Ji, Zhixuan Chen, Lin An, Naixin Zhang, Tao Yu, Xing-wang Li, Feng-ping Yang, Xueli Sun, Zaiquan Dong, Shun-ying Yu, Zhenghui Yi, Yifeng Xu, Lin He, Shaochang Wu, Longyou Zhao, C. Cai, G. He, Yi Shi
{"title":"Association between SLC17A7 gene polymorphisms and venlafaxine for major depressive disorder in a Chinese Han population: a prospective pharmacogenetic case-control study","authors":"Liangjie Liu, Decheng Ren, Fan Yuan, Yan Bi, Zhenming Guo, Gaini Ma, Fei Xu, Binyin Hou, Lei Ji, Zhixuan Chen, Lin An, Naixin Zhang, Tao Yu, Xing-wang Li, Feng-ping Yang, Xueli Sun, Zaiquan Dong, Shun-ying Yu, Zhenghui Yi, Yifeng Xu, Lin He, Shaochang Wu, Longyou Zhao, C. Cai, G. He, Yi Shi","doi":"10.1097/JBR.0000000000000096","DOIUrl":null,"url":null,"abstract":"Abstract Objective: Venlafaxine is a common antidepressant and its therapeutic effect varies among people with different genetic backgrounds. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the SLC17A7 gene are associated with the treatment outcome of venlafaxine in a Chinese Han population with major depressive disorder. Methods: This prospective pharmacogenetic case-control study that involved genotyping of four SNPs of SLC17A7 was conducted on 175 major depressive disorder patients of Chinese Han origin, aged 18 to 65 years, participated in the study from April 2005 to September 2006. Comparisons of allele and genotype frequencies of all SNPs were performed between the responder/remission group and the nonresponder/nonremission group. This study was approved by the Institutional Ethics Committee of Sichuan University (approval No. 20151112-265). Results: The allele and genotype frequencies of the four candidate SNPs in SCL17A7 showed no significant difference between responders and nonresponders. Meanwhile, no significant difference was detected in the four investigated SLC17A7 SNPs between patients who did and did not exhibit remission. Although one of the investigated SLC17A7 variants (rs1578944) demonstrated a significant association (P = 0.022) with a response to venlafaxine after 6 weeks of treatment in the survival analysis, the association was unclear after a Bonferroni multiple comparisons test was conducted. Conclusion: No significant association exists between the four candidate SNPs (rs1043558, rs1320301, rs1578944, and rs74174284) in SLC17A7 and venlafaxine treatment in the Chinese Han population.","PeriodicalId":150904,"journal":{"name":"Journal of Bio-X Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bio-X Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JBR.0000000000000096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Objective: Venlafaxine is a common antidepressant and its therapeutic effect varies among people with different genetic backgrounds. The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the SLC17A7 gene are associated with the treatment outcome of venlafaxine in a Chinese Han population with major depressive disorder. Methods: This prospective pharmacogenetic case-control study that involved genotyping of four SNPs of SLC17A7 was conducted on 175 major depressive disorder patients of Chinese Han origin, aged 18 to 65 years, participated in the study from April 2005 to September 2006. Comparisons of allele and genotype frequencies of all SNPs were performed between the responder/remission group and the nonresponder/nonremission group. This study was approved by the Institutional Ethics Committee of Sichuan University (approval No. 20151112-265). Results: The allele and genotype frequencies of the four candidate SNPs in SCL17A7 showed no significant difference between responders and nonresponders. Meanwhile, no significant difference was detected in the four investigated SLC17A7 SNPs between patients who did and did not exhibit remission. Although one of the investigated SLC17A7 variants (rs1578944) demonstrated a significant association (P = 0.022) with a response to venlafaxine after 6 weeks of treatment in the survival analysis, the association was unclear after a Bonferroni multiple comparisons test was conducted. Conclusion: No significant association exists between the four candidate SNPs (rs1043558, rs1320301, rs1578944, and rs74174284) in SLC17A7 and venlafaxine treatment in the Chinese Han population.
SLC17A7基因多态性与文拉法辛治疗中国汉族重度抑郁症的关系:一项前瞻性药物遗传学病例对照研究
摘要目的:文拉法辛是一种常见的抗抑郁药,其治疗效果在不同遗传背景的人群中存在差异。本研究的目的是探讨SLC17A7基因的单核苷酸多态性(snp)是否与文拉法辛在中国汉族重度抑郁症患者中的治疗效果有关。方法:对2005年4月至2006年9月参加研究的175例18 ~ 65岁汉族重度抑郁症患者进行SLC17A7 4个snp基因分型的前瞻性药物遗传学病例对照研究。比较反应组/缓解组和无反应组/非缓解组之间所有snp的等位基因和基因型频率。本研究经四川大学伦理委员会批准(批准号:20151112-265)。结果:SCL17A7 4个候选snp的等位基因频率和基因型频率在应答者和无应答者之间无显著差异。同时,在所研究的四个SLC17A7 snp中,出现缓解和未出现缓解的患者之间没有发现显著差异。尽管在生存分析中,其中一种SLC17A7变异(rs1578944)显示出与文拉法辛治疗6周后的应答显著相关(P = 0.022),但在进行Bonferroni多重比较检验后,这种关联尚不清楚。结论:中国汉族SLC17A7的4个候选snp (rs1043558、rs1320301、rs1578944和rs74174284)与文拉法辛治疗无显著相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信